ORIC Pharmaceuticals, Inc. (ORIC)
Develops cancer drugs designed to overcome tumor resistance to treatment
$11.87-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+17.3%
The outlook
ORIC trades at $11.87, positioned midway through its 52-week range and above both its 50- and 200-day moving averages. Analyst consensus is Strong Buy, with an average target implying 74% upside from the current price. The stock's technical positioning and analyst sentiment both lean constructive.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range60% of the way from its 52-week low to high
Price targetAvg target +74% vs current price
Analyst price target
~12-month · 13 analysts$20.69average target+74.3% vs now
Now $11.87
Low $14.00High $25.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.23B
52-wk high
$14.93
52-wk low
$7.23
50-day avg
$9.39
200-day avg
$10.63
Trailing P/E
—